Eureka Therapeutics, Inc. is a privately held clinical stage biotechnology company, headquartered in the San Francisco Bay area, focused on improving the safety profile of T cell therapies and developing T cell therapies for hematological malignancies and solid tumors. Eureka's core technology centers around its proprietary ARTEMIS™ T cell receptor platform and proprietary E-ALPHA phage display library for the discovery and engineering of human antibodies against intracellular targets via the MHC class I complex. The company is developing a pipeline of novel cancer therapeutics targeting intracellular oncogenes as well as cell-surface antigens.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 01/24/18 | $60,000,000 | Series D |
Acorn Pacific GP Capital | undisclosed |
